Paragon 28, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
February 29, 2024 at 04:03 pm
Share
Paragon 28, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was USD 216.39 million compared to USD 181.38 million a year ago. Net loss was USD 47.84 million compared to USD 67.33 million a year ago.
Basic loss per share from continuing operations was USD 0.58 compared to USD 0.88 a year ago. Diluted loss per share from continuing operations was USD 0.58 compared to USD 0.88 a year ago.
Paragon 28, Inc. is a medical device company. The Company develops, distributes, and sells medical devices in the foot and ankle segment of the orthopedic implant marketplace. Its products and product families include plates and plating systems, screws, staples, and nails to address all foot and ankle procedures, including fracture fixation, forefoot, or hallux valgus, which includes bunion and hammertoe, ankle, flatfoot, or progressive collapsing foot deformity (PCDF), Charcot foot and Ortho biologics. It provides a comprehensive portfolio of solutions that includes surgical implants and disposables, as well as surgical instrumentation. The Companyâs suite of surgical solutions comprises 75 product systems, including approximately 9,200 SKUs, which comprises of approximately 6,800 implants, 1,400 instruments and 1,000 disposable and other SKUs. Its products are available in a variety of sizes and configurations to suit the individual patientâs anatomical and surgical requirements.